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SUMMARY – Th e aim of the study was to evaluate the effi  cacy and safety of the new method of 
platelet-rich plasma activation in the form of platelet gel, used in the treatment of non-healing  chronic 
lower leg ulcers. Th e study was prospectively randomized, double blind and placebo controlled. We 
treated 60 patients (42 males and 18 females, mean age 69.43 years, SD 14.74) with chronic lower leg 
ulcers of diff erent etiologies. Th irty patients were treated with allogeneic platelet gel and 30 with 
 hydrogel. Both groups were comparable for duration of ulcer and its size. Treatment was repeated once 
a week for three consecutive weeks and then the last examination was scheduled at 6 months of the 
fi rst platelet gel application. Th e t-test was used to analyze independent samples. Healing of chronic 
wounds with platelet gel was statistically signifi cantly more eff ective compared to the treatment with 
hydrogel (p<0.05). At 6 months of platelet gel application, the mean wound area in the experimental 
group decreased to 35.01% (SD 53.69) of the initial wound size. In the control group, the wound area 
decreased to 89.95% (SD 71.82) of the initial wound size (p=0.001). Th e circumference of the wounds 
diminished to 54.62% (SD 39.85) of the initial value in the experimental group, compared to 91.28% 
(SD 29.32) in the control group (p<0.001). Allogeneic platelet gel prepared by the new  method used 
in this study was found to be a good treatment option for non-healing chronic wounds when other 
methods are ineff ective.
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Introduction
Platelets are small (1-3 μm)1, anuclear cell frag-
ments, derived in bone marrow from megakaryocytes 
by cellular fragmentation2-5. Platelet diff erentiation is 
directed by several growth factors, the most notable 
one being thrombopoietin2. Th eir lifespan is 7-9 days3, 
and the concentration of platelets in peripheral blood 
of a healthy adult is 150-350x109/L2,6,7.
Platelets contain at least 60 biologically active, pre-
synthesized molecules, e.g., cytoskeletal proteins, sig-
naling molecules, membrane protein, growth factors, 
coagulation proteins, adhesion molecules, cell-activat-
ing molecules, cytokines, integrins, infl ammatory mol-
ecules, and others2,3,8. Th ese molecules are stored in one 
of the three main types of platelet granules. Th e fi rst 
form of granules are dense granules. Th ere are 3-8 
dense granules per platelet; they are released by exocy-
tosis and contain several active substances (adenosine 
diphosphate/adenosine triphosphate (ADP/ATP), se-
rotonin, Ca2+)9,10. Th ere are 50-80 alpha (α) granules 
per platelet10,11, and they release a plethora of diff erent 
growth factors, chemokines and cytokines9,10. Al-
though there are more than 300 diff erent proteins in 
α-granules11,12, it seems that the most important 
growth factors in platelets are the three isomers of 
platelet-derived growth factor (PDGF) αα, ββ and αβ, 
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transforming growth factor (TGF)-α and -β, vascular 
endothelial growth factor (VEGF) and epidermal 
growth factor (EGF), since they initiate wound heal-
ing13,14.
Also of importance are other growth factors found 
in platelets, i.e. fi broblast growth factors (FGFs), insu-
lin-like growth factor (IGF), platelet-derived endo-
thelial growth factor (PDEGF), platelet-derived an-
giogenesis factor (PDAF), interleukin-8 (IL-8), tumor 
necrosis factor (TNF)-α, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), keratinocyte 
growth factor (KGF) and angiopoietin-2 (Ang-2)2. All 
of the above-mentioned growth factors participate in 
tissue healing, infl uencing mechanisms such as che-
motaxis, cell proliferation, cell diff erentiation, removal 
of cell debris, angiogenesis, immune modulation, anti-
microbial activity and tissue remodeling2,3,11,15. Th e last 
type of platelet granules are lysosomes that contain 
enzymes responsible for protein induction and matrix 
regeneration (cathepsins D and E, elastase, acid hydro-
lases)9,10,16.
When platelets adhere to the exposed molecules of 
injured epithelium or bind physiological agonists such 
as thrombin, ADP, collagen, thromboxane A2, epi-
nephrine or platelet-activating factors, they get acti-
vated3. Th is process leads to rapid shape change of the 
platelet, to development of pseudopodia because of 
cytoskeleton reorganization, and fi nally to platelet ag-
gregation1,2.
Platelet activation also causes release of the con-
tents of α-granules into the surrounding environment 
due to their fusion with platelet plasma membrane, 
known as degranulation10,17. Th e majority (95%) of the 
pre-synthesized contents of platelet granules is re-
leased within 1 hour of the activation, while additional 
growth factors are synthesized and released until the 
end of the platelet lifetime13.
Besides their role in hemostasis, where platelets 
help prevent blood loss at the site of injury, they also 
play an important role in immune defense, tissue 
forming and regeneration2,10,16. Because of these fi nd-
ings, platelets were started to be successfully used for 
faster healing of chronic wounds. To date, there are 
only few studies that focus on the eff ectiveness of the 
use of the autologous platelet rich plasma (PRP) and 
platelet gel for the purpose of accelerating healing of 
chronic wounds. Th e aim of this study was to expand 
the knowledge about PRP and to evaluate the effi  cacy 
and safety of the new method of PRP activation into a 
platelet gel used for the treatment of non-healing 
chronic lower leg ulcers.
Patients, Materials and Methods
Th roughout the procedure, local and European 
regulations and restrictions for tissue and cell products 
were followed. Both participating institutions (Uni-
versity Medical Centre Ljubljana and Department of 
Surgical Infections and Blood Transfusion Centre, 
Slovenia) acquired an accreditation by the Public 
Agency of the Republic of Slovenia for Medicinal 
Products and Medical Devices. Th e Republic of Slove-
nia National Medical Ethics Committee approved the 
study.
Sixty patients (42 males and 18 females, mean age 
69.43 years, SD 14.74) with chronic ulcer of diff erent 
etiology on lower extremity were enrolled in the pro-
spective randomized controlled double blind trial. 
Th irty patients were treated with allogeneic platelet gel 
(experimental group) and 30 patients in control group 
with placebo hydrogel (Tegaderm; 3M, USA). Th e pa-
tients in both groups were comparable for ulcer dura-
tion and ulcer size (mean area 14.51 cm2, SD 23.14, 
range 0.1-136.2 cm2; mean circumference 13.53 cm, 
SD 10.77, range 1.6-53.8 cm). In both groups, we 
treated venous ulcers (n=12), arterial ulcers (n=12), 
diabetic ulcers (n=30) and non-healed ulcers following 
injury (n=6). Inclusion criteria were absence of local 
and systemic signs of infl ammation, previous known 
malignancy, autoimmune diseases and absence of 
pregnancy. Laboratory parameters in the majority of 
patients before treatment (diff erential blood count, 
electrolytes, urea, creatinine, albumins, proteins, iron, 
C-reactive protein, erythrocyte sedimentation rate, 
liver function tests, tests of hemostasis) were within 
the normal limits. No anti-platelet antibodies were de-
tected in the blood of any patient.
Blood group of the platelet gel recipient was deter-
mined (ABO, RhD). After identifi cation of a possible 
donor (matching ABO RhD group), her/his written 
consent was obtained and blood was drawn to test for 
the presence of viral markers. Since platelet gel was 
considered a tissue/cell product, tests were performed 
as required by local regulations, including lues, hepati-
tis B surface antigen (HBsAg), antibodies to the hepa-
titis B core antigen (anti-HBc) and hepatitis B surface 
Danijela Semenič et al. Th e eff ectiveness of allogeneic platelet gel
436 Acta Clin Croat, Vol. 57, No. 3, 2018
antigen (anti-HBs), hepatitis C antibody (anti-HCV), 
combined testing for human immunodefi ciency virus 
antibody and p24 antigen (anti-HIV 1/2/0, HIVp24Ag), 
hepatitis B virus DNA (HBV DNA), hepatitis C virus 
RNA (HCV RNA) and HIV1 RNA.
Buff y coat was released from the quarantine when 
the donor blood sample was reported to be negative 
for viral markers and it was confi rmed that the blood 
group of a donor matched that of a platelet gel recipi-
ent. Further processing started no later than 24 hours 
after the blood drawing. Buff y coat of the donor’s 
blood was irradiated with 30 Gy from a Cs-137 source, 
using the Gammacell 1000 Elite (Best Th eratronics, 
Canada) irradiation device.
After irradiation, processing continued in clean 
rooms (grade A-grade D environment as required by 
local regulation for tissue/cell processing). Buff y coat 
was transferred to the centrifuge tube and spun at 
1500 g for 8 minutes without a break. Th e top-most 
layer (PRP) was transferred to the fresh tube. PRP was 
sampled for sterility testing using a Becton Dickinson 
Bactec 9050 (Becton Dickinson, USA) system and the 
platelet, red and white blood cell count was measured. 
PRP was stored at room temperature until platelet ac-
tivation. All PRPs were used within 24 hours of prepa-
ration.
Outpatient treatment was performed at the outpa-
tient unit of the Department of Surgical Infections, 
University Medical Centre Slovenia. At the beginning 
of the study, blood laboratory testing was performed and 
swabs of the wounds for microbiological examination 
were collected. Patients were examined once a week. 
Platelets in PRP were activated in the aseptic operating 
room using adjusted doses of components Beriplast P 
Combi-Set 1 mL: thrombin 500 IU/mL + 40 mmol 
CaCl2 1 mL + aprotinin 100 KIU (Kallikrein Inactiva-
tor Unit, corresponding to 0.056 PEU, PEU = Ph. Eur 
Unit, 1 PEU= 1800 KIU) + fi brinogen 9 mg + coagula-
tion factor XIII 6U (1 Unit (U) corresponds to Factor 
XIII activity of 1 mL fresh citrated plasma, pooled plas-
ma of healthy donors). Gelatinous mixture (i.e. platelet 
gel) was formed within 5 minutes after the addition of 
activation components and was applied to the cleaned 
wound no later than 5.5 minutes after PRP activation.
After wound irrigation with the local antiseptic so-
lution polyhexamethylenebiguanide (PHMB) 0.1% 
with Betaine 0.1% (Prontosan; B Braun, Germany) 
and sharp cleaning with the gauze, platelet gel or hy-
drogel (Tegaderm; 3M, USA) were applied to the 
wound bed and covered with silicone-polyurethane 
wound dressing (Mepilex; Mölnlycke, Sweden). Th e 
surrounding skin was protected using a neutral fat 
cream (20% olive oil in linola fat). Treatment was re-
peated once per week for three consecutive weeks. 
Digital photos of the wounds were obtained every 
week before gel application.
For wound image analysis, specially developed dig-
ital image analysis algorithm, Wound ManagerTM, 
based on artifi cial intelligence, was used. Wound area, 
circumference, and wound healing rate (WH, calcu-
lated as relative weekly change of wound area) were 
presented graphically and numerically. Th e informa-
tion about percentages of diff erent tissue types within 
the wound (granulation tissue, fi brin, necrosis) were 
manually marked on the selected wound photographs. 
At the end of the study, blood laboratory examination 
and swabs of the wounds for microbiological examina-
tion were performed again (Tables 1 and 2).













































































p <0.001 0.005 0.849 0.413 0.462 0.878 0.036 0.003
CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; SD = standard deviation; p = level of statistical signiffi  cance of between-
-group diff erences
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Statistical analysis
Student’s t-test was used to analyze diff erences be-
tween the groups. All analyses were performed by use 
of PASW statistics 18.0 (IBM, USA). Healing of 
chronic wounds was assessed by calculating the per-
centage of the mean wound area and circumference 
reduction at 6 months of treatment as compared with 
the values recorded before treatment.
Results
Six months after fi rst platelet gel application, the 
mean area of the wounds in experimental group de-
creased to 35.01% (SD 53.69) of the initial value com-
pared to 89.95% (SD 71.82) in control group, p=0.001. 
Circumference of the wounds was reduced to 54.62% 
(SD 39.85) of the initial value for experimental group 
and to 91.28% (SD 29.32) for control group, p<0.001. 
Healing of chronic wounds with platelet gel was statis-
tically signifi cant when compared to the treatment 
with hydrogel (p<0.05) (Fig. 1).
Laboratory blood values and infl ammation param-
eters in the blood were in the normal limits for both 
groups and did not vary signifi cantly before and after 
treatment (Tables 1 and 2). In addition, the type of 
bacteria has not changed statistically signifi cantly be-
fore and after treatment (Table 3).
None of the patients treated with platelet gel de-
veloped maceration of the surrounding skin, while 
maceration was observed in 75% of patients in the 
control group despite the skin being protected with 
oily cream.
No systemic or local side eff ects or adverse reac-
tions were observed during the topical treatment, and 
no platelet antibodies were detected in the systemic 
blood circulation of the patients who had received 
platelet gel.
Discussion
Traditionally, platelet activation is achieved by add-
ing thrombin and calcium to PRP. When platelets in 
the autologous PRP get activated, platelet gel is 
formed18. It was fi rst developed in the early 1970s. Th e 
fi rst clinical use of platelet-fi brinogen-thrombin mix-
ture as a ‘corneal adhesive’ dates from 19752,19. In 1979, 
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anastomosis2,20. In recent years, the use of platelet gel 
has been extended to diff erent surgical fi elds21. Th e fact 
that fi brin can drive fi broblast migration and collagen 
deposition, leading to granulation tissue formation, 
also off ered the possibility of using platelet gel in the 
treatment of tissue defects2,22.
Th e strategy to promote wound healing is to pre-
pare PRP/platelet gel and administer it to the sites of 
surgical interventions, injuries and chronic non-heal-
ing wounds, thus delivering growth factors directly to 
the wound site2,7. Th e mechanism of action is thought 
to be the molecular and cellular induction of normal 
 Case 1 Case 2 Case 3
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wound healing responses, similar to the one triggered 
by platelet activation18,23,24.
In addition to pain, chronic wounds on lower ex-
tremities also cause reduced mobility of the patient and, 
as such, strongly aff ect the quality of life25. Th erefore, 
platelet gel was used for topical treatment of diff erent 
chronic wounds. When autologous platelets were used 
for chronic venous leg ulcers in a randomized trial as 
adjuvant therapy, no signifi cant eff ect on healing was 
observed26. Similarly, there was no infl uence on healing 
of chronic venous ulceration in another randomized 
study using topical application of autologous platelet 
lysate27. In a systematic meta-analysis of the effi  cacy and 
safety of PRP, results showed no signifi cant diff erences 
in complete epithelialization of skin ulcers between the 
experimental and control groups21.
More success has been achieved in the treatment of 
diabetic neuropathic foot ulcers28, where topically ap-
plied CT-102 APST signifi cantly accelerated wound 
closure in diabetic leg ulcers29. Th is is of great impor-
tance because patients with diabetes mellitus have an 
increased risk of developing peripheral artery disease. 
Diabetes in association with critical ischemia of limbs 
is independently associated with an increased risk of 
mortality30.
A systematic review and meta-analysis in cutane-
ous hard-heal acute and chronic wounds demonstrated 
that PRP therapy improved complete and partial 
wound healing when compared with standard wound 
care24,31.
In the platelet gel, autologous platelets are most 
commonly used. However, there are several advantages 
to the use of allogeneic platelets instead. Allogeneic 
platelet units from the blood bank are usually available 
in larger quantities, are safe, aff ordable and highly 
standardized in terms of platelet count, residual leuko-
cyte and red blood cell content. In addition, the condi-
tions for their preparation are mandated by interna-
tional standards in the USA and Europe (the centrifu-
gal forces used for their isolation, the temperature of 
centrifugation, techniques of separation and process-
ing, and the composition of the preservative solu-
tion)2,32.
Within the platelet gel, platelets are located in fi -
brin network, where they continually excrete bioactive 
substances and growth factors, which diff use into the 
surrounding area3. For optimization of activation and 
stability of the gel, we developed a new method. Be-
sides commonly used activation of PRP with throm-
bin and calcium, we also added fi brinogen (factor 1) 
and factor XIII. Th e former was converted to fi brin by 
thrombin and the latter strengthened the cross-linking 
of fi brin molecules. We also added aprotinin, an antifi -
brinolytic molecule that inhibits proteolytic enzymes 
and thus slows down fi brinolysis and increases the 
consistency and stability of the platelet gel.
Th e characteristics of platelet products for transfu-
sion are well specifi ed while the minimum require-
ments for PRP are less clear33. Although there seems 
to be a consensus on the minimum number of platelets 
in the fi nal product13, there is much less information 
on the number of other blood cell types in the PRP 
that can have an eff ect on its effi  cacy. Leukocytes con-
tain and produce cytokines that are catabolically active 




















Pseudomonas aeruginosa 8 7 0.573 12 13 0.326
Morganella morganii 4 3 0.326 4 4 1.000
Escherichia coli 6 7 0.326 4 4 1.000
Staphylococcus aureus 13 15 0.423 12 11 0.326
Streptococcus agalactiae 3 5 0.161 5 5 1.000
Corynebacterium striatum 2 2 1.000 4 4 1.000
Stenotrophomonas maltophilia 1 3 0.161 1 1 1.000
Proteus mirabilis 1 1 1.000 2 2 1.000
Enterococcus faecalis 2 4 0.326 1 1 1.000
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and might infl uence the infl ammatory phase of the 
wound-healing process but they can also have an im-
portant antimicrobial role in PRP34. Th erefore, we 
wanted to ensure at least minimal standardization of 
the PRPs we used. Since single donor platelets are a 
standard blood bank product, residual white and red 
blood cell content is highly standardized35. Th e maxi-
mum amount of the red and white blood cells in PRP 
was therefore determined based on the standard36.
Laboratory blood tests (complete blood count, 
electrolytes, urea, creatinine, albumins, proteins, iron, 
C-reactive protein, erythrocyte sedimentation rate, 
liver function tests, tests of hemostasis) were carried 
out in order to detect the possible systemic eff ects of 
platelet gel and hydrogel treatment. We found that the 
results were similar before and after treatment in all 
cases, which means that the use of hydrogel and allo-
geneic platelet gel had no systemic eff ects.
Our results suggest that the new method of PRP 
activation using not only a combination of calcium 
and thrombin, but also aprotinin, fi brinogen and co-
agulation factor XIII, is more effi  cient in treating 
chronic ulcers of diff erent etiologies. We upgraded the 
formula of precursors and increased stability of the 
platelet gel. Th e modern non-adhesive dressings ab-
sorb the new harder formula of platelet gel less than 
liquid form, so it stays on the wound longer when 
compared to the standard liquid consistency. Conse-
quently, its eff ects also last longer. Th is therapy is safe 
and painless and the patient can be followed up in an 
outpatient clinic. Th e improved method could be an 
alternative treatment option for non-healing chronic 
wounds where other methods have failed.
In the so far published literature, PRP in wound 
healing of diff erent etiology shows promising re-
sults11,37-40, and so do the results of our study. Th is 
method is superior to others because of increased sta-
bility of platelet gel with prolongation of the eff ect. It 
could be the gold standard of treatment option.
In the past years, quality of life has gained ever more 
attention in medicine, and patients treated with PRP 
heal faster, returning to normal life and its quality.
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Sažetak
USPJEŠNOST LIJEČENJA KRONIČNIH RANA ALOGENIM TROMBOCITNIM GELOM 
U USPOREDBI S HIDROGELOM: PROSPEKTIVNO ISTRAŽIVANJE
D. Semenič, T. Cirman, P. Rožman i D. M. Smrke
Cilj ove studije bio je procijeniti djelotvornost i sigurnost nove metode aktivacije plazme bogate trombocitima u obliku 
trombocitnog gela koji se rabi za liječenje kroničnih ulkusa potkoljenice koji ne cijele. Studija je bila prospektivno randomi-
zirana, dvostruko slijepa i placebom kontrolirana. Liječili smo 60 bolesnika (42 muškarca, 18 žena, srednje dobi od 69,43 
godine, SD 14,74) s kroničnim ulkusima potkoljenice različitih etiologija. Po 30 bolesnika liječeno je alogenim trombocitnim 
gelom odnosno hidrogelom. Obje skupine bile su usporedive po trajanju ulkusa i njegovoj veličini. Liječenje se ponavljalo 
jednom tjedno tijekom tri uzastopna tjedna i tada je posljednji pregled obavljen 6 mjeseci od prve primjene trombocitnog 
gela. Za analizu nezavisnih uzoraka primijenjen je t-test. Liječenje kroničnih rana trombocitnim gelom bilo je statistički 
značajno učinkovitije u odnosu na liječenje hidrogelom (p<0,05). Šest mjeseci nakon aplikacije gela srednja vrijednost 
 površine rana u eksperimentalnoj skupini smanjila se na 35,01% (SD 53,69) početne veličine rane. U kontrolnoj skupini 
područje rana smanjilo se na 89,95% (SD 71,82), p=0,001. Opseg rana smanjio se na 54,62% (SD 39,85) početne vrijednosti 
u eksperimentalnoj skupini u usporedbi s 91,28% (SD 29,32) u kontrolnoj skupini (p<0,001). Alogeni trombocitni gel pri-
premljen novom metodom koja se rabila u ovom istraživanju dobar je izbor za liječenje kroničnih rana koje ne cijele kada 
druge metode nisu učinkovite.
Ključne riječi: Plazma bogata trombocitima; Noga, čir; Rana, cijeljenje
